Latest Hodgkin's Lymphoma News
Reduced-intensity Treatment May be Effective for Early Hodgkin’s Lymphoma (8/27/2010)
Among patients with early-stage Hodgkin’s lymphoma and a favorable prognosis, it may be possible to reduce the number of chemotherapy cycles and the dose of radiation therapy without adversely affecting outcome. The results of this study were published in the New England Journal of Medicine.
Study Confirms that Radiation Therapy Is Not Necessary in Patients with Favorable, Limited-stage Hodgkin’s Lymphoma (4/4/2010)
Researchers from the Dana-Farber Cancer Center have confirmed prior studies that indicate chemotherapy alone is safe and effective for the treatment of early-stage Hodgkin’s Lymphoma in appropriate patients. The details of this study were published in a recent issue of the Journal of Clinical Oncology.
Childhood Cancer Survivors Treated with Radiation Therapy at Increased Risk of Death from Heart Disease in Adulthood (3/26/2010)
A dose of as little as 5 Gy of radiation therapy to the heart for the treatment of childhood cancers results in a significant increase in cardiac death later in life, according to a study recently published in the Journal of Clinical Oncology.
Allogeneic Stem Cell Transplantation Viable for Children and Adolescents with Relapsed Hodgkin’s Lymphoma (9/24/2009)
Children and adolescents with relapsed Hodgkin’s lymphoma respond well to allogeneic stem cell transplantation, according to the results of a study published in Blood.
September Is National Leukemia and Lymphoma Awareness Month (8/28/2009)
As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Hodgkin's Lymphoma News By Topic
Hodgkin's Lymphoma - Early StageReduced-intensity Treatment May be Effective for Early Hodgkin’s Lymphoma (8/27/2010)
Among patients with early-stage Hodgkin’s lymphoma and a favorable prognosis, it may be possible to reduce the number of chemotherapy cycles and the dose of radiation therapy without adversely affecting outcome. The results of this study were published in the New England Journal of Medicine.
Study Confirms that Radiation Therapy Is Not Necessary in Patients with Favorable, Limited-stage Hodgkin’s Lymphoma (4/4/2010)
Researchers from the Dana-Farber Cancer Center have confirmed prior studies that indicate chemotherapy alone is safe and effective for the treatment of early-stage Hodgkin’s Lymphoma in appropriate patients. The details of this study were published in a recent issue of the Journal of Clinical Oncology.
Childhood Cancer Survivors Treated with Radiation Therapy at Increased Risk of Death from Heart Disease in Adulthood (3/26/2010)
A dose of as little as 5 Gy of radiation therapy to the heart for the treatment of childhood cancers results in a significant increase in cardiac death later in life, according to a study recently published in the Journal of Clinical Oncology.
September Is National Leukemia and Lymphoma Awareness Month (8/28/2009)
As the month of September brings leukemia and lymphoma into focus, it’s time to increase public understanding of these diseases, including their prevalence, approaches to screening and prevention, treatment options, and resources that offer updated leukemia and lymphoma information throughout the year.
Hodgkin’s Survivors at Increased Risk of Stroke (6/24/2009)
Patients who have been treated with radiation therapy for Hodgkin’s lymphoma have an elevated risk of stroke. These results were published in the Journal of the National Cancer Institute.
Hodgkin's Lymphoma - Advanced StageHodgkin’s Survivors at Increased Risk of Stroke (6/24/2009)
Patients who have been treated with radiation therapy for Hodgkin’s lymphoma have an elevated risk of stroke. These results were published in the Journal of the National Cancer Institute.
The American Society of Clinical Oncology 2008: Advances in Treatment of Lymphoma and Chronic Lymphocytic Leukemia (2/2/2009)
At the 2008 meeting of the American Society of Clinical Oncology (ASCO), there were more than 100 abstracts devoted to the treatment of lymphoma. There is increasing evidence that survival of patients with lymphoma and chronic lymphocytic leukemia (CLL) is steadily increasing. New drugs are being developed at a reasonable rate, which creates the question of how best to incorporate all the available drugs in an optimal manner. Additionally, there appears to be significant progress in reduced-intensity allogeneic stem cell transplants for low-grade lymphomas.
Survival Rates Improving in Childhood Hematologic Cancers (9/29/2008)
Five- and 10-year survival rates in childhood hematalogic cancers have significantly improved since 1990, according to the results of a study recently published in the Journal of the National Cancer Institute.
Hodgkin’s Lymphoma Survivors May Be at Risk for Secondary Cancer (2/29/2008)
Hodgkin’s lymphoma survivors may be at risk for secondary cancer. These findings were recently reported in the British Journal of Cancer.
Better Prognosis for Patients with Lymphocyte-predominant Hodgkin’s Lymphoma (2/5/2008)
A recent study compared lymphocyte-predominant Hodgkin’s lymphoma (LPHL) and classical Hodgkin’s lymphoma (cHL) in order to define differences in patient characteristics and possible treatment options for both types of disease. These results were published in the Journal of Clinical Oncology.
Hodgkin's Lymphoma - Progressive RelapsedAllogeneic Stem Cell Transplantation Viable for Children and Adolescents with Relapsed Hodgkin’s Lymphoma (9/24/2009)
Children and adolescents with relapsed Hodgkin’s lymphoma respond well to allogeneic stem cell transplantation, according to the results of a study published in Blood.
Hodgkin’s Survivors at Increased Risk of Stroke (6/24/2009)
Patients who have been treated with radiation therapy for Hodgkin’s lymphoma have an elevated risk of stroke. These results were published in the Journal of the National Cancer Institute.
Gemzar®/Navelbine® Effective and Well-tolerated in Children with Relapsed/Refractory Hodgkin’s Disease (5/7/2009)
The combination of Gemzar® (gemcitabine) and Navelbine® (vinorelbine) appears to be effective and well-tolerated for reinduction in children with relapsed or refractory Hodgkin’s disease, according to the results of a study published in the Journal of Clinical Oncology.
Autologous Stem Cell Transplantation Effective for Relapsed Hodgkin’s Lymphoma (7/31/2008)
Autologous stem cell transplantation is effective for patients with Hodgkin’s lymphoma that has progressed following prior therapies. These results were recently published in the Annals of Oncology.
Patients with Hodgkin’s at Risk for Heart Attack Later in Life (2/14/2007)
According to results from the Journal of the National Cancer Institute, patients treated for Hodgkin’s lymphoma are at an increased risk for death from a heart attack for 25 years.
|
